Neurological Drugs Flashcards
Name 4 drugs dopaminergic drugs for Parkinson’s disease?
- Levodopa: as Co-Beneldopa
- Levodopa: as Co-Careldopa
- Ropinirole
- Pramipexol
Madopar is a combination drug used in the treatment of Parkinson’s disease (antiparkinsonian), what are the two active ingredients?
- Levodopa
2. Benserazide
Sinemet is another combination drug, as with madopar it is an antiparkinsonian agent, what are the two active ingredients?
- Levodopa
- Carbidopa
- Co-careldopa
What is the important safety information to be aware of related to antiparkinsonian use? (madopar and sinemet).
Treatment with levodopa is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. If the patient develops an impulse control disorder, levodopa should be withdrawn or the dose reduced until the symptoms resolve.
What are the cautions associated with antiparkinsonian agents? (7)
People with:
- Cushing’s syndrome
- Diabetes
- Endocrine disorders
- History of convulsions
- History of MI with arrhythmias
- Osteomalacia
- Phaechromocytoma
What are the common side effects associated with antiparkinsoniam drugs? (21)
- Abnormal dreams
- Anorexia
- Anxiety
- Confusion/Dementia
- Depression
- Chorea
- Dizziness
- Drowsiness
- Dry mouth
- Dyskinesia
- Dystonia
- Euphoria
- Fatigue
- Insomnia
- Nausea
- Palpitations
- Postural hypotension
- Psychosis
- Syncope
- Taste disturbances
- Vomiting
What are the 3 specific indications for use of dopaminergic drugs for Parkinson’s disease?
- Early Parkinson’s disease
- Later Parkinson’s disease
- Secondary Parkinsonism
Which dopaminergic drugs are more commonly prescribed in early Parkinson’s disease? (2)
- Ropinirole
2. Pramipexol
Which drug is an integral part of management in later Parkinson’s disease?
Levodopa
What is secondary Parkinsonism?
Parkinsonian symptoms due to a cause other than idiopathic Parkinson’s disease
Briefly what is Parkinson’s disease and what is the mechanism of action of dopaminergic drugs?
In Parkinson’s disease, there is a deficiency of dopamine in the nigrostriatal pathway that links the substantia nigra in the midbrain to the corpus striatum in the basal ganglia. Via direct and indirect circuits, this causes the basal ganglia to exert greater inhibitory effects on the thalamus which, in turn, reduces excitatory input to the motor cortex. This generates the features of Parkinson’s disease, such as bradykinesia and rigidity.
Treatment seeks to increase dopaminergic stimulation to the striatum. It is not possible to give dopamine itself because it does not cross the blood-brain barrier. By contrast, levodopa (L-dopa) is a precursor of dopamine that can enter the brain via a membrane transporter. Ropinirole and pramipexol are relatively selective agonists for the D2-receptor, which predominates in the striatum.
What is the major problem with levodopa?
The ‘wearing off effect’, where the patient’s symptoms worsen towards the end of the dosage interval. This tends to get worse as duration of therapy increases. It can be partially overcome by increasing the dosage or frequency but this can generate the opposite effect: excessive and involuntary movements at the beginning of the dosage internal.
Why is levodopa always given in combination with another drug?
Levodopa is always given with a peripheral dopa-decarboxylase inhibitor (e.g. carbidopa) to reduce its conversion to dopamine outside the brain. This interaction reduces nausea and lowers the dose needed for therapeutic effect.
Which drugs should dopaminergic agents not be combined with?
- Antipsychotics
- Metoclopramide
Their effects on dopamine receptors are contradictory.
What is the indication for use of phenytoin?
- Status epilepticus - to control seizures, where benzodiazepines are ineffective
- Epilepsy - to reduce the frequency of generalised or focal seizures (although drugs with fewer side effects are usually preferred).
What is the mechanism of action of phenytoin?
The mechanism is incompletely understood. Phenytoin reduces neuronal excitability and electrical conductance among brain cells, which inhibits the spread of seizure activity. It appears to do this by binding to neuronal Na+ channels in their inactive state, prolonging inactivity and preventing Na+ influx into the neurone. This prevents a drift in membrane potential from the resting (-70mV) to the threshold (-55mV) value required to trigger an action potential. A similar effect in cardiac Purkinje fibres may account for both antiarrhythmic and cardiotoxic effects of phenytoin.
What are the side effects associated with appearance, when using phenytoin?
Long-term phenytoin treatment can cause a change in appearance: skin coarsening, acne, hirsutism and gum hypertrophy.
What are the neurological side effects associated with taking phenytoin?
Dose-related neurological effects include cerebellar toxicity (e.g. nystagmus, ataxia and discoordination) and impaired cognition or consciousness.
What other side effects are associated with phenytoin use?
- Haematological disorders & osteomalacia - by inducing folic acid and vitamin D metabolism
- Hypersensitivity reactions
- Phenytoin toxicity –> cardiovascular collapse and respiratory depression
What is the warning associated with phenytoin use, in relation to therapeutic window and toxicity?
Phenytoin is metabolised by the liver with zero-order kinetics (at a constant rate irrespective of plasma concentrations) for concentrations at or above the therapeutic range. Moreover, the therapeutic index is low, implying that the safety margin between therapeutic and toxic doses is narrow.